secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2026-10-14T12:10:32+00:00
Accession:  0001104659-26-115745
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

MaxCyte preliminary Q3 core revenue ~$8.1M, up 26% YoY; raises FY2026 revenue guidance to ~$34M
--------------------------------------------------------------------------------

- Q3 2026 preliminary core business revenue ~$8.1M, up 26% YoY; SPL Program-related revenue over $1.0M, including a $1.0M milestone received in Q3.
- FY2026 revenue guidance raised to ~$34M from prior $30M-$32M: core business ~$28M (prior $25M-$27M) and SPL Program ~$6M (prior ~$5M).
- SPL guidance includes ~$4M of milestone payments and ~$2M of commercial royalties; this was MaxCyte's second SPL milestone of 2026.
- CEO Maher Masoud cites accelerated instrument purchasing from a large customer pulled forward from Q4; core business up ~15% YoY in H2 2026.
- Royalty revenue and full results due Nov 10, 2026; two SPL-partner pivotal trials have potential approval as early as next year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000110465926115745/0001104659-26-115745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000110465926115745/tm2627568d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-115745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer